Supplementary Table 8: Details of included studies: bevacizumab

Study (year) - **Design**	**Population (*n*)**	**Prior chemotherapy (*n*)**	**Bevacizumab therapy**	**Mean duration of follow-up in months (range)**	**Outcome**			**Adverse events (*n*)**
					Radiological response (*n*)	**Biochemical response (*n*)**	**Progression-free survival**	
Burman (2022) - Cohort	APT (5) - corticotroph (3) - lactotroph (1) - NFPA (1) PC (6) - somatotroph (1) - lactotroph (4) - silent (1)	TMZ (4) TMZ + capecitabine (1) TMZ (3) TMZ + ICI (1) TMZ + lomustine, carboplatin + paclitaxel (1) None (1)	Dose n.r. NB add-on to TMZ in 1 patient, combined with 5-FU in 1 patient	Treatment duration 8.6 (1-28)	APT: CR◊ 0% SD◊ 20% (1), durability of effect 16 months PD◊ 60% (3) Stopped due to other condition (1) PC: CR◊ 0% PR◊ 17% (1), durability of effect 16 months. NB SD for metastases, durability of effect 15 months SD◊ 33% (2), durability of effect 7 and 7.5 months PD◊ 50% (3)	-	-	n.a.

APT = aggressive pituitary tumour
PC = pituitary carcinoma
NFPA = nonfunctioning pituitary adenoma
TMZ = temozolomide
ICI = immune checkpoint inhibition
5-FU = 5-fluorouracil

n.r. = not reported
n.a. = not assessed

◊ According to the following criteria:
CR = complete response: disappearance of all lesions
PR = partial response: ≥ 30% reduction in tumour volume
SD = stable disease: change in tumour volume between ≤ 30% decrease and ≤ 10% increase from baseline
PD = progressive disease: ≥ 10% increase in tumour volume